AI Verdict
KBR has stronger fundamentals based on our AI analysis.
KBR vs KAPA Fundamental Comparison
| Metric | KBR | KAPA |
|---|---|---|
| Revenue | $7.8B | N/A |
| Net Income | $415.0M | $-5.4M |
| Net Margin | 5.3% | N/A |
| ROE | 27.6% | -85.9% |
| ROA | 6.3% | -83.3% |
| Current Ratio | 1.22x | 27.07x |
| Debt/Equity | 1.73x | 0.00x |
| EPS | $3.21 | $-0.30 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KBR vs KAPA: Frequently Asked Questions
Is KBR or KAPA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KBR has stronger fundamentals. KBR is rated HOLD (72% confidence) while KAPA is rated SELL (85% confidence). This is not investment advice.
How does KBR compare to KAPA fundamentally?
KBR, INC. has ROE of 27.6% vs Kairos Pharma, LTD.'s -85.9%. Net margins are 5.3% vs N/A respectively.
Which stock pays higher dividends, KBR or KAPA?
KBR has a dividend yield of N/A or no dividend while KAPA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KBR or KAPA for long term?
For long-term investing, consider that KBR has HOLD rating with 72% confidence, while KAPA has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KBR vs KAPA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KBR vs KAPA, the AI consensus favors KBR based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.